Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1252 in Relapsed/Refractory Myelofibrosis
NCT04354727Phase 2Withdrawn
- Sponsor
- Ascentage Pharma
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pelcitoclax in myelofibrosis (MF), sponsored by Ascentage Pharma. Planned start Dec 2020; status: withdrawn.
02
Drugs
pelcitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04354727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354727.